Literature DB >> 17406430

Production and characterization of adeno-associated viral vectors.

Joshua C Grieger1, Vivian W Choi, R Jude Samulski.   

Abstract

The adeno-associated virus (AAV) is one of the most promising viral vectors for human gene therapy. As with any potential therapeutic system, a thorough understanding of it at the in vitro and in vivo levels is required. Over the years, numerous methods have been developed to better characterize AAV vectors. These methods have paved the way to a better understanding of the vector and, ultimately, its use in clinical applications. This review provides an up-to-date, detailed description of essential methods such as production, purification and titering and their application to characterize current AAV vectors for preclinical and clinical use.

Entities:  

Mesh:

Year:  2006        PMID: 17406430     DOI: 10.1038/nprot.2006.207

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  278 in total

1.  Two-photon single-cell optogenetic control of neuronal activity by sculpted light.

Authors:  Bertalan K Andrasfalvy; Boris V Zemelman; Jianyong Tang; Alipasha Vaziri
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-11       Impact factor: 11.205

2.  Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic.

Authors:  Edward M Kennedy; Anand V R Kornepati; Adam L Mefferd; Joy B Marshall; Kevin Tsai; Hal P Bogerd; Bryan R Cullen
Journal:  Methods       Date:  2015-08-17       Impact factor: 3.608

3.  Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors.

Authors:  Angela M Mitchell; R Jude Samulski
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

4.  Cell Cycle-Dependent Expression of Adeno-Associated Virus 2 (AAV2) Rep in Coinfections with Herpes Simplex Virus 1 (HSV-1) Gives Rise to a Mosaic of Cells Replicating either AAV2 or HSV-1.

Authors:  Francesca D Franzoso; Michael Seyffert; Rebecca Vogel; Artur Yakimovich; Bruna de Andrade Pereira; Anita F Meier; Sereina O Sutter; Kurt Tobler; Bernd Vogt; Urs F Greber; Hildegard Büning; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

5.  A novel role for brain interleukin-6: facilitation of cognitive flexibility in rat orbitofrontal cortex.

Authors:  Jennifer J Donegan; Milena Girotti; Marc S Weinberg; David A Morilak
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

6.  Astrocytes influence the severity of spinal muscular atrophy.

Authors:  Hansjörg Rindt; Zhihua Feng; Chiara Mazzasette; Jacqueline J Glascock; David Valdivia; Noah Pyles; Thomas O Crawford; Kathryn J Swoboda; Teresa N Patitucci; Allison D Ebert; Charlotte J Sumner; Chien-Ping Ko; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2015-04-24       Impact factor: 6.150

7.  AAV-mediated gene editing via double-strand break repair.

Authors:  Matthew L Hirsch; R Jude Samulski
Journal:  Methods Mol Biol       Date:  2014

8.  Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells.

Authors:  Benjamin M Gaub; Michael H Berry; Amy E Holt; Andreas Reiner; Michael A Kienzler; Natalia Dolgova; Sergei Nikonov; Gustavo D Aguirre; William A Beltran; John G Flannery; Ehud Y Isacoff
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

9.  Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain.

Authors:  Eleni A Markakis; Kenneth P Vives; Jeremy Bober; Stefan Leichtle; Csaba Leranth; Jeff Beecham; John D Elsworth; Robert H Roth; R Jude Samulski; D Eugene Redmond
Journal:  Mol Ther       Date:  2009-12-15       Impact factor: 11.454

10.  Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals.

Authors:  A Asokan; J S Johnson; C Li; R J Samulski
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.